Press releases

WINNIPEG, Manitoba (December 7, 2004) - Further to the Company news release issued December 6, 2004 with respect to a proposed non-brokered private placement of up to 3,000,000 units (the "Private Placement"), Kane Biotech Inc. (TSX-V:KNE) reports that certain insiders have arranged the sale of an aggregate of 355,834 common shares at a price of $0.45 per share through the facilities of the TSX Venture Exchange. The proceeds from this sale will be used to subscribe for 355,834 common shares of Kane Biotech pursuant to the previously announced Private Placement.
The Private Placement is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange. Any common shares issued pursuant to the Private Placement will be subject to a four-month hold period in accordance with the requirements of the TSX Venture Exchange and applicable securities laws.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. The Company's technology focuses on the genetic mechanisms of biofilm formation, and builds upon the discovery of over 60 novel anti-biofilm targets. Biofilms are microbial populations in a self-produced matrix able to withstand high temperatures, host immune responses and antibiotics.

For more information, please contact:

Marcus Enns
President
Kane Biotech Inc.
204-487-2328 phone
204-488-9823 fax
info@kanebiotech.com
www.kanebiotech.com

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. This release is not to be construed as an offer to sell, or a solicitation for an offer to buy or trade securities